Achieve Life Sciences (ACHV) Competitors $3.26 -0.07 (-1.96%) As of 11:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACHV vs. ZBIO, MYGN, RIGL, EBS, VSTM, XOMA, VNDA, LXRX, CDXS, and AGENShould you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Zenas Biopharma (ZBIO), Myriad Genetics (MYGN), Rigel Pharmaceuticals (RIGL), Emergent BioSolutions (EBS), Verastem (VSTM), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Lexicon Pharmaceuticals (LXRX), Codexis (CDXS), and Agenus (AGEN). These companies are all part of the "biotechnology" industry. Achieve Life Sciences vs. Its Competitors Zenas Biopharma Myriad Genetics Rigel Pharmaceuticals Emergent BioSolutions Verastem XOMA Vanda Pharmaceuticals Lexicon Pharmaceuticals Codexis Agenus Zenas Biopharma (NASDAQ:ZBIO) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk, community ranking and media sentiment. Is ZBIO or ACHV more profitable? Zenas Biopharma's return on equity of 0.00% beat Achieve Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Zenas BiopharmaN/A N/A N/A Achieve Life Sciences N/A -108.30%-65.20% Does the media prefer ZBIO or ACHV? In the previous week, Zenas Biopharma had 19 more articles in the media than Achieve Life Sciences. MarketBeat recorded 21 mentions for Zenas Biopharma and 2 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.93 beat Zenas Biopharma's score of -0.01 indicating that Achieve Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 20 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Achieve Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor ZBIO or ACHV? Achieve Life Sciences received 330 more outperform votes than Zenas Biopharma when rated by MarketBeat users. However, 100.00% of users gave Zenas Biopharma an outperform vote while only 70.46% of users gave Achieve Life Sciences an outperform vote. CompanyUnderperformOutperformZenas BiopharmaOutperform Votes4100.00% Underperform VotesNo VotesAchieve Life SciencesOutperform Votes33470.46% Underperform Votes14029.54% Do analysts prefer ZBIO or ACHV? Zenas Biopharma presently has a consensus price target of $36.67, indicating a potential upside of 239.51%. Achieve Life Sciences has a consensus price target of $14.33, indicating a potential upside of 340.35%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than Zenas Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zenas Biopharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Achieve Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Do institutionals and insiders believe in ZBIO or ACHV? 33.5% of Achieve Life Sciences shares are owned by institutional investors. 16.5% of Zenas Biopharma shares are owned by company insiders. Comparatively, 3.0% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation and earnings, ZBIO or ACHV? Achieve Life Sciences has lower revenue, but higher earnings than Zenas Biopharma. Zenas Biopharma is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZenas Biopharma$15M30.12-$148.51M-$3.55-3.04Achieve Life SciencesN/AN/A-$29.82M-$1.34-2.43 SummaryAchieve Life Sciences beats Zenas Biopharma on 9 of the 16 factors compared between the two stocks. Get Achieve Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACHV vs. The Competition Export to ExcelMetricAchieve Life SciencesDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$112.90M$2.70B$5.61B$8.54BDividend YieldN/A0.70%5.28%4.17%P/E Ratio-2.887.8027.1819.77Price / SalesN/A34.79411.66152.70Price / CashN/A15.7538.3234.64Price / Book-46.505.386.984.63Net Income-$29.82M-$65.73M$3.24B$248.14M7 Day Performance-15.01%-3.43%-0.29%-0.46%1 Month Performance22.83%-0.24%8.48%4.16%1 Year Performance-36.05%-20.90%32.16%13.35% Achieve Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACHVAchieve Life Sciences2.211 of 5 stars$3.26-2.0%$14.33+340.3%-36.4%$112.90MN/A-2.8820ZBIOZenas Biopharma1.298 of 5 stars$10.06+5.7%$36.67+264.5%N/A$420.85M$15M-2.83N/ATrending NewsHigh Trading VolumeMYGNMyriad Genetics4.0568 of 5 stars$4.46+6.4%$14.79+231.5%-78.0%$411.11M$831.30M-3.432,600High Trading VolumeRIGLRigel Pharmaceuticals3.3115 of 5 stars$20.15+4.9%$36.40+80.6%+113.0%$360.12M$203.08M143.94160Positive NewsAnalyst RevisionGap DownEBSEmergent BioSolutions4.1457 of 5 stars$6.30-0.3%$14.33+127.5%+4.6%$341.95M$930.30M-1.542,420Gap DownVSTMVerastem3.2267 of 5 stars$6.02-19.9%$13.63+126.3%+65.2%$330.79M$10M-1.8950Positive NewsHigh Trading VolumeXOMAXOMA4.2231 of 5 stars$24.22-2.2%$69.50+187.0%-1.6%$289.84M$13.05M-6.9610Positive NewsGap DownVNDAVanda Pharmaceuticals4.7039 of 5 stars$4.30-0.9%$16.50+283.7%-21.8%$253.42M$201.35M-13.44290Positive NewsAnalyst RevisionLXRXLexicon Pharmaceuticals2.6999 of 5 stars$0.62-0.8%$3.67+489.9%-63.6%$224.70M$31.21M-0.83140Positive NewsGap DownCDXSCodexis3.9704 of 5 stars$2.25-2.2%$8.00+255.6%-31.8%$186.40M$49.82M-2.59250Positive NewsAnalyst RevisionGap UpAGENAgenus4.2246 of 5 stars$4.13+20.4%$9.00+117.9%-71.5%$113.23M$99.52M-0.37440Gap UpHigh Trading Volume Related Companies and Tools Related Companies ZBIO Alternatives MYGN Alternatives RIGL Alternatives EBS Alternatives VSTM Alternatives XOMA Alternatives VNDA Alternatives LXRX Alternatives CDXS Alternatives AGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACHV) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achieve Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Achieve Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
